Terfenadine, the first non-sedating antihistamine

Area of Science:

• Pharmacology
• Allergy Research
• Medicinal Chemistry

Background:

• Histamine H1-receptor antagonists are crucial for managing allergic disorders.
• Classical antihistamines often cause central nervous system (CNS) side effects like sedation.
• There is a need for antihistamines with improved safety profiles and efficacy.

Purpose of the Study:

• To characterize the pharmacological profile of terfenadine.
• To investigate the mechanism of action and receptor binding kinetics of terfenadine.
• To evaluate the clinical efficacy and CNS penetration of terfenadine.

Main Methods:

• In vitro receptor binding assays to determine antagonism.
• In vitro and ex vivo studies on histamine H1-receptor association/dissociation kinetics.
• Radioactive disposition and autoradiographic studies to assess brain penetration.
• Clinical trials for allergic rhinitis and skin conditions.

Main Results:

• Terfenadine acts as a potent H1-receptor antagonist with dualistic competitive and unsurmountable inhibition.
• It exhibits slow dissociation from H1-receptors compared to chlorpheniramine.
• Terfenadine and its metabolites show minimal brain penetration, correlating with lack of CNS effects.
• Clinically effective in treating allergic rhinitis and skin conditions without sedation or psychomotor impairment.

Conclusions:

• Terfenadine represents a novel antihistamine with a distinct pharmacological profile.
• Its lack of CNS effects and potent H1-receptor antagonism offer significant clinical advantages.
• Terfenadine is a promising therapeutic agent for histamine-associated disorders.